Antimicrobial Resistance and Tuberculosis Prevalence in Africa: A Public Health Concern

References

[1] Boehme, C. C., Nabeta, P., Hillemann, D., et al. (2010). Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine, 363(11), 1005-1015.

[2] Chokshi, D. A., et al. (2019). The global impact of antimicrobial resistance: Insights and challenges for public health. Global Health, 15, 35.

[3] Cohen, K. A., et al. (2019). Evolution of extensively drug-resistant tuberculosis over four decades: Whole genome sequencing and phylogenetics. bioRxiv, 232156.

[4] Corbett, E. L., et al. (2003). The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine, 163(9), 1009-1021.

[5] Cox, H., et al. (2018). Multidrug-resistant tuberculosis treatment outcomes in Africa. European Respiratory Journal, 51(3), 1800023.

[6] Gelband, H., & Delahoy, M. J. (2013). Addressing antimicrobial resistance in low-income and middle-income countries. BMJ Global Health, 3(Suppl 1), S54-S57.

[7] Getahun, H., et al. (2012). Management of tuberculosis and HIV coinfection. WHO Bulletin, 90(11), 877–895.

[8] Jassal, M., & Bishai, W. R. (2010). Extensively drug-resistant tuberculosis. The Lancet Infectious Diseases, 10(9), 633-646.

[9] Kaufmann, S. H. E., & McMichael, A. J. (2005). Annulling a dangerous liaison: HIV and tuberculosis. The Lancet, 366(9484), 913-915.

[10] Lawn, S. D., & Churchyard, G. (2009). Epidemiology of HIV-associated tuberculosis. Current Opinion in HIV and AIDS, 4(4), 299-305.

[11] Nathanson, E., et al. (2010). Multidrug-resistant tuberculosis management in resource-limited settings. Emergency Infectious Diseases, 16(6), 890.

[12] Raviglione, M. C., & Uplekar, M. W. (2006). WHO's DOTS strategy for TB control. Tuberculosis, 86(5), 503-516.

[13] Chokshi, D. A., et al. (2019). The global impact of antimicrobial resistance: Insights and challenges for public health. Global Health, 15, 35.

[14] Cohen, K. A., et al. (2019). Evolution of extensively drug-resistant tuberculosis over four decades: Whole genome sequencing and phylogenetics. bioRxiv, 232156.

[15] Corbett, E. L., et al. (2003). The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine, 163(9), 1009-1021.

[16] Gelband, H., & Delahoy, M. J. (2013). Addressing antimicrobial resistance in low-income and middle-income countries. BMJ Global Health, 3(Suppl 1), S54-S57.

[17] Jassal, M., & Bishai, W. R. (2010). Extensively drug-resistant tuberculosis. The Lancet Infectious Diseases, 10(9), 633-646.

[18] Lawn, S. D., & Churchyard, G. (2009). Epidemiology of HIV-associated tuberculosis. Current Opinion in HIV and AIDS, 4(4), 299-305.

[19] Nathanson, E., et al. (2010). Multidrug-resistant tuberculosis management in resource-limited settings. Emergency Infectious Diseases, 16(6), 890.

[20] Raviglione, M. C., & Uplekar, M. W. (2006). WHO's DOTS strategy for TB control. Tuberculosis, 86(5), 503-516.

[21] WHO. (2021). Global Tuberculosis Report 2021. Geneva: World Health Organization.

[22] Yagui, M., et al. (2006). The magnitude of drug-resistant tuberculosis in Peru. International Journal of Tuberculosis and Lung Disease, 10(7), 740-746.

[23] Swaminathan, S., & Ramachandran, R. (2015). Challenges in tackling tuberculosis in HIV coinfected persons. Indian Journal of Medical Research, 141(4), 410-420.

[24] WHO. (2020). Global Tuberculosis Report 2020. Geneva: World Health Organization.

[25] WHO. (2021). Global Tuberculosis Report 2021. Geneva: World Health Organization.

[26] Yagui, M., et al. (2006). The magnitude of drug-resistant tuberculosis in Peru. International Journal of Tuberculosis and Lung Disease, 10(7), 740-746.

[27] Zignol, M., et al. (2006). Global incidence of multidrug-resistant tuberculosis. Journal of Infectious Diseases, 194(4), 479-485.

@article{1706588,
      author = {Adewale Adeboye Adewole, Samuel Paul Gyamfi, Jesseline Mwinila Eledi},
      title = {Antimicrobial Resistance and Tuberculosis Prevalence in Africa: A Public Health Concern},
      journal = {Iconic Research And Engineering Journals},
      year = {2024},
      volume = {8},
      number = {5},
      pages = {755-765},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1706588.pdf},
      abstract = {Tuberculosis (TB) remains a critical public health issue in Africa, where antimicrobial resistance (AMR) is severely impacting TB treatment effectiveness, leading to increased morbidity and mortality. This research examines the prevalence of TB in Africa, the rising rates of AMR in TB strains, and the primary drivers behind these trends. Through an analysis of socio-economic factors, healthcare infrastructure challenges, and the misuse of antibiotics, this study provides insight into the factors contributing to AMR in TB. Furthermore, this research explores interventions to reduce AMR and improve TB treatment outcomes, including policy reforms, improved diagnostics, and increased funding for healthcare and public awareness initiatives. Findings underscore the urgent need for a coordinated approach to managing AMR in TB to mitigate the public health risks facing African nations.},
      keywords = {Tuberculosis (TB), Antimicrobial Resistance (AMR), Mortality, Healthcare.},
      month = {November},
  }